NMRA Earnings Date: Nov 5, 2026 (Estimated) — Neumora Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
Updated
When is NMRA's next earnings date?
Neumora Therapeutics, Inc. Common Stock (NMRA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19.
How did NMRA do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Neumora Therapeutics, Inc. Common Stock posted EPS of -$0.23 versus the -$0.24 estimate, a beat of 4.2%. Revenue was $0. The stock's 1-day post-earnings move was -7.5%.
How much does NMRA stock move after earnings?
NMRA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.5% (up or down) in the day after earnings.
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.24 | -0.23 | +4.17% | $0 | ✅ Beat | -7.51% | -12.43% | -42.23% |
| 2026-05-07 | Q1 2026 | -0.31 | -0.30 | +3.23% | $0 | ✅ Beat | -16.74% | -23.61% | -30.04% |
| 2026-03-30 | Q4 2025 | -0.33 | -0.35 | -6.06% | $0 | ❌ Miss | -17.17% | -9.01% | -3.43% |
| 2025-11-06 | Q3 2025 | -0.34 | -0.35 | -2.94% | $0 | ❌ Miss | -1.53% | +9.16% | -15.27% |
| 2025-08-06 | Q2 2025 | -0.37 | -0.33 | +10.81% | $0 | ✅ Beat | +3.77% | -1.89% | +5.97% |
| 2025-05-12 | Q1 2025 | -0.38 | -0.42 | -10.53% | $0 | ❌ Miss | -1.89% | -0.29% | +33.10% |
| 2025-03-03 | Q4 2024 | -0.37 | -0.37 | +0.00% | $0 | ➖ Inline | -9.94% | -4.49% | -35.90% |
| 2024-11-12 | Q3 2024 | -0.39 | -0.45 | -15.38% | $0 | ❌ Miss | -17.08% | -27.86% | -22.87% |
Showing last 8 quarters.